In order to satisfy the market demand of efficient anti-hepatitis C virus(HCV) drugs and effectively cure tens of millions of Chinese patients infected with HCV, under the leadership of the founder Dr. Zhan, AB pharma has successfully developed the " all-genotypes efficient new drugs (ZN2007 and ZN6168) with double targets (NS3/4A and NS5A) against hepatitis C virus (HCV)", and has been achievedsignificant periodical results. At present, the above Class 1.1 new drug has been applied and obtained patents of invention globally withindependent intellectual property rights.

The clinical trials of two kinds of all-genotypes highly effective anti-HCV new drugs with double-targets are being moved forward, and all clinical trials are expected to be completed around the end of 2020, and then start to sell globally.


021-5442 6122
©2018 AB Pharma Ltd. All rights reserved
沪公网安备 33311802006333号 沪CP备12345767号
Technical Support:www.51eway.com
No. 99, Lane 133, Guangzhong Road, Shanghai